⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy Study of Ifabond in Breast Cancer Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy Study of Ifabond in Breast Cancer Surgery

Official Title: A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection

Study ID: NCT01742975

Interventions

IFABOND (TM)

Study Description

Brief Summary: A randomized prospective simple-blind interventional study evaluating the efficacy of the synthetic adhesive solution "Ifabond", in patients undergoing breast cancer surgery. The main objective of this study is to determine if the application of Ifabond, in addition to the conventional method of breast surgery, reduces the postoperative seroma formation. The secondary objective is to assess quality of life immediately after surgery, and the need for needle aspiration of the axilla, when using Ifabond.

Detailed Description: Breast cancer patients will be selected at their preoperative visit with the surgeon, who will inform them about the study and answer their questions. Patients who consent to participate will be randomized to one of two arms: 1. Arm A: Applying Ifabond 2. Arm B: Without Ifabond Patients will be stratified according to these two criteria: 1. Axillary Lymph Node Dissection planned (ALND) 2. Body Mass Index (BMI) The following parameters will be measured: * ECOG status and Blood Pressure at day 3(day 7 in case of ALND), day 15 and day 30 post surgery * Volume of drainage at day 3 and at (day 7 in case of ALND)post surgery * Discomfort alleged by the patient at day 3(day 7 in case of ALND), day 15 and day 30 post surgery * Lymphocele volume measured by ultrasound at day 15 and day 30 post surgery * If the volume is ≥ 100cc, a needle aspiration will be performed, and the volume of aspirate will be documented. * Adverse events and concomitant medications will be collected throughout the study until 30 days after the last ultrasound.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Hôpital Euroépen Marseille, Marseille, Paca, France

Centre de Chirurgie Gynecologique Et Des Maladies Du Sein, Grenoble, Rhône-Alpes, France

Contact Details

Name: Michel CONTE, MD

Affiliation: Hôpital Européen Marseille

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: